(HOLX) Hologic - Ratings and Ratios
Diagnostics, Imaging, Surgery, Skeletal
HOLX EPS (Earnings per Share)
HOLX Revenue
Description: HOLX Hologic October 30, 2025
Hologic, Inc. (NASDAQ: HOLX) develops, manufactures, and markets diagnostics, medical imaging, and surgical solutions focused on women’s health, operating through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The firm’s portfolio includes Aptima molecular assays (viral load, bacterial vaginosis, SARS-CoV-2), ThinPrep cytology systems, 3-D digital mammography and related breast-cancer tools, as well as hysteroscopic and orthopedic devices such as MyoSure, NovaSure, and the Horizon DXA scanner.
Key performance indicators from the most recent fiscal year (FY 2023) show total revenue of approximately $5.0 billion, with the Diagnostics segment contributing roughly 55 % of sales and delivering a 14 % operating margin-both above the median for the health-care equipment sub-industry. The Breast Health segment grew 7 % YoY, driven by continued adoption of 3-D mammography, while the GYN Surgical line posted a 5 % increase, reflecting expanding minimally invasive procedures in outpatient settings.
Sector-wide, two macro drivers underpin Hologic’s growth outlook: (1) an aging female population that raises demand for bone-density (DXA) and breast-cancer screening services, and (2) sustained reimbursement pressure on diagnostic assays, which creates a pricing-discipline environment but also incentivizes higher-value, multiplex test platforms. A caveat is that Hologic’s reliance on U.S. Medicare/Medicaid reimbursement rates introduces regulatory-policy uncertainty that could affect future margins.
For a deeper quantitative assessment, you may find ValueRay’s analyst platform useful for drilling into HOLX’s financial metrics and peer comparisons.
HOLX Stock Overview
| Market Cap in USD | 16,450m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1990-06-21 |
HOLX Stock Ratings
| Growth Rating | -6.65% |
| Fundamental | 70.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -18.0% |
| Analyst Rating | 3.45 of 5 |
HOLX Dividends
Currently no dividends paidHOLX Growth Ratios
| Growth Correlation 3m | 56.3% |
| Growth Correlation 12m | -14.7% |
| Growth Correlation 5y | -12.8% |
| CAGR 5y | -0.82% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.02 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.05 |
| Sharpe Ratio 12m | -0.49 |
| Alpha | -18.67 |
| Beta | 0.627 |
| Volatility | 20.95% |
| Current Volume | 4739.6k |
| Average Volume 20d | 3703.2k |
| Stop Loss | 71.8 (-3.1%) |
| Signal | 0.51 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (557.1m TTM) > 0 and > 6% of Revenue (6% = 242.3m TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA -0.30pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 60.88% (prev 75.10%; Δ -14.22pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 1.07b > Net Income 557.1m (YES >=105%, WARN >=100%) |
| Net Debt (787.3m) to EBITDA (1.01b) ratio: 0.78 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.55 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (225.5m) change vs 12m ago -4.65% (target <= -2.0% for YES) |
| Gross Margin 51.80% (prev 55.14%; Δ -3.34pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 45.65% (prev 44.85%; Δ 0.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.15 (EBITDA TTM 1.01b / Interest Expense TTM 120.4m) >= 6 (WARN >= 3) |
Altman Z'' 4.42
| (A) 0.28 = (Total Current Assets 3.42b - Total Current Liabilities 962.5m) / Total Assets 8.81b |
| (B) 0.37 = Retained Earnings (Balance) 3.22b / Total Assets 8.81b |
| (C) 0.08 = EBIT TTM 740.2m / Avg Total Assets 8.85b |
| (D) 0.79 = Book Value of Equity 3.14b / Total Liabilities 3.96b |
| Total Rating: 4.42 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 70.16
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 5.72% = 2.86 |
| 3. FCF Margin 24.22% = 6.06 |
| 4. Debt/Equity 0.52 = 2.37 |
| 5. Debt/Ebitda 0.78 = 2.04 |
| 6. ROIC - WACC (= 0.99)% = 1.24 |
| 7. RoE 11.51% = 0.96 |
| 8. Rev. Trend 14.00% = 1.05 |
| 9. EPS Trend 51.83% = 2.59 |
What is the price of HOLX shares?
Over the past week, the price has changed by +0.26%, over one month by +9.40%, over three months by +9.08% and over the past year by -6.55%.
Is Hologic a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HOLX is around 66.96 USD . This means that HOLX is currently overvalued and has a potential downside of -9.64%.
Is HOLX a buy, sell or hold?
- Strong Buy: 3
- Buy: 3
- Hold: 14
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the HOLX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 75 | 1.2% |
| Analysts Target Price | 75 | 1.2% |
| ValueRay Target Price | 73.9 | -0.3% |
HOLX Fundamental Data Overview November 04, 2025
P/E Trailing = 30.6681
P/E Forward = 14.9254
P/S = 4.0729
P/B = 3.1192
P/EG = 1.5076
Beta = 0.627
Revenue TTM = 4.04b USD
EBIT TTM = 740.2m USD
EBITDA TTM = 1.01b USD
Long Term Debt = 2.51b USD (from longTermDebt, last quarter)
Short Term Debt = 3.40m USD (from shortTermDebt, last quarter)
Debt = 2.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 787.3m USD (from netDebt column, last quarter)
Enterprise Value = 17.09b USD (16.45b + Debt 2.52b - CCE 1.88b)
Interest Coverage Ratio = 6.15 (Ebit TTM 740.2m / Interest Expense TTM 120.4m)
FCF Yield = 5.72% (FCF TTM 978.2m / Enterprise Value 17.09b)
FCF Margin = 24.22% (FCF TTM 978.2m / Revenue TTM 4.04b)
Net Margin = 13.79% (Net Income TTM 557.1m / Revenue TTM 4.04b)
Gross Margin = 51.80% ((Revenue TTM 4.04b - Cost of Revenue TTM 1.95b) / Revenue TTM)
Gross Margin QoQ = 56.32% (prev 38.00%)
Tobins Q-Ratio = 1.94 (Enterprise Value 17.09b / Total Assets 8.81b)
Interest Expense / Debt = 1.15% (Interest Expense 28.9m / Debt 2.52b)
Taxrate = 17.06% (40.1m / 235.0m)
NOPAT = 613.9m (EBIT 740.2m * (1 - 17.06%))
Current Ratio = 3.55 (Total Current Assets 3.42b / Total Current Liabilities 962.5m)
Debt / Equity = 0.52 (Debt 2.52b / totalStockholderEquity, last quarter 4.84b)
Debt / EBITDA = 0.78 (Net Debt 787.3m / EBITDA 1.01b)
Debt / FCF = 0.80 (Net Debt 787.3m / FCF TTM 978.2m)
Total Stockholder Equity = 4.84b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.33% (Net Income 557.1m / Total Assets 8.81b)
RoE = 11.51% (Net Income TTM 557.1m / Total Stockholder Equity 4.84b)
RoCE = 10.07% (EBIT 740.2m / Capital Employed (Equity 4.84b + L.T.Debt 2.51b))
RoIC = 8.34% (NOPAT 613.9m / Invested Capital 7.36b)
WACC = 7.35% (E(16.45b)/V(18.97b) * Re(8.33%) + D(2.52b)/V(18.97b) * Rd(1.15%) * (1-Tc(0.17)))
Discount Rate = 8.33% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.12%
[DCF Debug] Terminal Value 76.58% ; FCFE base≈992.7m ; Y1≈950.1m ; Y5≈923.2m
Fair Price DCF = 70.16 (DCF Value 15.62b / Shares Outstanding 222.6m; 5y FCF grow -5.69% → 3.0% )
EPS Correlation: 51.83 | EPS CAGR: 10.53% | SUE: 1.53 | # QB: 1
Revenue Correlation: 14.00 | Revenue CAGR: 2.63% | SUE: 2.02 | # QB: 1
Additional Sources for HOLX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle